FDA 483 - Inopak Ltd - August 03, 2023
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
An FDA inspection of Inopak Ltd, a drug manufacturer in Ringwood, NJ, revealed significant deficiencies in its quality control unit regarding contract-manufactured OTC drug products. The firm failed to establish and follow written procedures for quality control, including evaluating formulations, reviewing laboratory results, and managing batch records. Additionally, Inopak Ltd did not perform essential testing, such as for benzene content and microbiological contamination, on finished products distributed to the U.S. market.
ID · ab7aec18-099a-4858-9a57-11015b64c8c1